Serum Biomarkers of Iron Status and Risk of Primary Liver Cancer: A Systematic Review and Meta-Analysis

Tran, Kim; Coleman, Helen; McCain, R Stephen; Cardwell, Chris R

doi:10.1080/01635581.2019.1609053

Cited by 34 publications

(30 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results are in line with abundant data from observational and experimental studies, indicating carcinogenic effects of high iron levels on liver cancer. In a recent meta-analysis of cohort and case-control studies, serum ferritin (6 studies) and serum iron (3 studies) levels in the highest category were associated with 1.5-and 2.5-fold increases in risk of liver cancer, respectively, when compared to levels in the lowest group [9]. Moreover, high transferrin saturation (≥60% versus <50%) was reported to be associated with a significant 5.9-fold higher risk of liver cancer in a prospective cohort of 8763 Danish adults followed up for 15 years [24].…”

Section: Discussionmentioning

confidence: 99%

“…A randomized trial of 1277 individuals with peripheral arterial disease (636 in iron reduction group through venesection and 641 in control group) found that in the iron reduction group, who received regular phlebotomy, the risk of overall cancer, cancer-specific mortality and all-cause mortality was lower than in the control group after 4.5 years of follow-up [4]. However, findings of observational studies are inconsistent or scarce concerning the effects of iron status on individual cancers, such as colorectal, breast and oesophagal cancer [5][6][7][8][9][10][11]. Consequently, whether iron status (which is routinely measured in clinical practice as serum iron, transferrin saturation, ferritin and transferrin) plays a role in the development of site-specific cancer remains inconclusive.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Iron Status and Cancer Risk in UK Biobank: A Two-Sample Mendelian Randomization Study

et al. 2020

View full text Add to dashboard Cite

We conducted a two-sample Mendelian randomization study to explore the associations of iron status with overall cancer and 22 site-specific cancers. Single-nucleotide polymorphisms for iron status were obtained from a genome-wide association study of 48,972 European-descent individuals. Summary-level data for breast and other cancers were obtained from the Breast Cancer Association Consortium and UK Biobank. Genetically predicted iron status was positively associated with liver cancer and inversely associated with brain cancer but not associated with overall cancer or the other 20 studied cancer sites at p < 0.05. The odds ratios of liver cancer were 2.45 (95% CI, 0.81, 7.45; p = 0.11), 2.11 (1.16, 3.83; p = 0.02), 10.89 (2.44, 48.59; p = 0.002) and 0.30 (0.17, 0.53; p = 2 × 10−5) for one standard deviation increment of serum iron, transferrin saturation, ferritin and transferrin levels, respectively. For brain cancer, the corresponding odds ratios were 0.69 (0.48, 1.00; p = 0.05), 0.75 (0.59, 0.97; p = 0.03), 0.41 (0.20, 0.88; p = 0.02) and 1.49 (1.04, 2.14; p = 0.03). Genetically high iron status was positively associated with liver cancer and inversely associated with brain cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Iron Status and Cancer Risk in UK Biobank: A Two-Sample Mendelian Randomization Study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…For these reasons, SF is widely used as a surrogate marker of iron stores. In addition to this, SF has been found to be elevated in patient with inflammation, liver disease, and malignancy . Moreover, previous studies have suggested that high SF is associated with poor prognosis in pancreatic cancer, colorectal cancer, lung cancer, peripheral T‐cell lymphoma, and hepatocellular carcinoma .…”

Section: Introductionmentioning

confidence: 92%

“…In addition to this, SF has been found to be elevated in patient with inflammation, liver disease, and malignancy. [8][9][10][11] Moreover, previous studies have suggested that high SF is associated with poor prognosis in pancreatic cancer, colorectal cancer, lung cancer, peripheral T-cell lymphoma, and hepatocellular carcinoma. [12][13][14][15][16] Therefore, ferritin may not only function as a marker of iron stores, but may also aid in clinical decision-making, including diagnosis, prognosis, treatment, and/or patient management.…”

Section: Introductionmentioning

confidence: 99%

Reference intervals established using indirect method for serum ferritin assayed on Abbott Architect i2000_SR analyzer in Chinese adults

Wang

Guo²,

et al. 2019

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background Serum ferritin (SF) test has been widely used in clinical practice. However, its reference intervals (RIs) vary depending on the analytical method and ethnic origin. This study was to establish the RIs using indirect method for SF in Chinese adults. Methods SF was assayed on Abbott i2000SR analyzer. The SF test results of all health examinees (8913 males aged 18‐93 years and 5397 females aged 18‐90 years) between December 2010 and April 2019 were obtained from our laboratory information system. After Box‐Cox transformation of raw data and exclusion of outliers, parametric and non‐parametric approaches were used to calculate 95% RIs. The correlation between SF levels and ages, and the differences in SF levels between subgroups were also analyzed. Results SF levels in females were significantly different from those in males (Z = 88.96, Z* = 23.17; Z > Z*) and showed a weak positive correlation with age (r = .466, P < .0001). The RIs based on parametric approach in males were 66.12‐561.58 µg/L, whereas in all females were 3.59‐269.59 µg/L, females aged <50 years 3.26‐148.02 µg/L and those aged ≥50 years 17.28‐303.27 µg/L. The RIs based on non‐parametric approach in males were 65.00‐571.37 µg/L whereas in all females were 4.00‐254.00 µg/L, females aged <50 years 4.00‐152.00 µg/L and those aged ≥50 years 16.00‐304.05 µg/L. Conclusions Our indirect RIs for SF were markedly different from the manufacturer's recommended RIs and might be more suitable for Chinese adults, which would be helpful in interpreting laboratory data and clinical decision‐making.

show abstract

“…In the lung, increased levels of lipocalin are associated with radio-responsiveness and this protein could serve as an early-stage biomarker [89,90]. Direct measurements of serum Fe concentration were evaluated for possible association with cancer, however, results were not always consistent between studies [91][92][93][94].…”

Section: Iron and Fe-proteins As Cancer Biomarkersmentioning

confidence: 99%

Iron Dysregulation in Human Cancer: Altered Metabolism, Biomarkers for Diagnosis, Prognosis, Monitoring and Rationale for Therapy

Lelièvre

Sancey

Coll

et al. 2020

Preprint

View full text Add to dashboard Cite

Iron (Fe) is a trace element that plays essential roles in various biological processes such as DNA synthesis and repair, as well as cellular energy production, or oxygen transport, and it is currently widely recognized that iron homeostasis is dysregulated in many cancers. Indeed, several iron homeostasis proteins may be responsible for malignant tumor initiation, proliferation, and for metastatic spread of tumors. A large number of studies demonstrated the potential clinical value of turning these deregulated proteins as prognostic and/or predictive biomarkers of malignancy and /or response to anticancer treatments. Additionally, the iron addiction of cancer cells and the importance of iron in ferroptosis cell death signaling pathways prompted the development of therapeutic strategies against advanced stage or resistant cancers. In this review, we selected relevant and promising studies in the field of iron metabolism in cancer research and clinical oncology. Besides, we discuss some co-existing discrepant findings. We will also present and discuss the latest lines of research related to targeting iron, or its regulatory pathways, as potential promising anti-cancer strategies for human therapy. Iron chelators, such as deferoxamine or iron-oxide based nanoparticles, which are already tested in clinical trials, alone or in combination with chemotherapy will also be reported.

show abstract

Serum Biomarkers of Iron Status and Risk of Primary Liver Cancer: A Systematic Review and Meta-Analysis

Abstract: Serum biomarkers of iron status and risk of primary liver cancer: A systematic review and meta-analysis.

Cited by 34 publications

References 28 publications

Iron Status and Cancer Risk in UK Biobank: A Two-Sample Mendelian Randomization Study

Iron Status and Cancer Risk in UK Biobank: A Two-Sample Mendelian Randomization Study

Reference intervals established using indirect method for serum ferritin assayed on Abbott Architect i2000_SR analyzer in Chinese adults

Iron Dysregulation in Human Cancer: Altered Metabolism, Biomarkers for Diagnosis, Prognosis, Monitoring and Rationale for Therapy

Contact Info

Product

Resources

About

Serum Biomarkers of Iron Status and Risk of Primary Liver Cancer: A Systematic Review and Meta-Analysis

Abstract: Serum biomarkers of iron status and risk of primary liver cancer: A systematic review and meta-analysis.

Cited by 34 publications

References 28 publications

Iron Status and Cancer Risk in UK Biobank: A Two-Sample Mendelian Randomization Study

Iron Status and Cancer Risk in UK Biobank: A Two-Sample Mendelian Randomization Study

Reference intervals established using indirect method for serum ferritin assayed on Abbott Architect i2000SR analyzer in Chinese adults

Iron Dysregulation in Human Cancer: Altered Metabolism, Biomarkers for Diagnosis, Prognosis, Monitoring and Rationale for Therapy

Contact Info

Product

Resources

About

Reference intervals established using indirect method for serum ferritin assayed on Abbott Architect i2000_SR analyzer in Chinese adults